Living A Healthy Life

LIVING A HEALTHY LIFE

Health is a value and a responsibility we put above everything else.

Krka is one of the leading generic pharmaceutical companies with 70 years of experience. Today, the high quality of our products is recognised all over the world. Our achievements have been built by generations of Krka employees through their courageous and visionary outlook.

Our attitude to people, the environment and the natural heritage as well as our strategic business direction all contribute to a better quality of life.

Movie about Krka

Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.

News

25. 1. 2024

2023 Krka Group Performance Estimate

The Management Board of Krka, d. d. held a press conference today presenting the Krka Group 2023 preliminary unaudited performance results, which the Krka Supervisory Board had discussed at its meeting yesterday. The Krka Group generated €1,806.4 million of revenue last year, up €88.9 million, or 5%, compared to 2022.

25. 1. 2024

Establishment of a joint venture in India

Krka and Laurus Labs Ltd. from India have reached an agreement to establish a joint venture company Krka Pharma Pvt. Ltd. in Hyderabad, India. Krka will hold 51% and Laurus 49% share in the joint venture. The registered capital of the newly founded company amounts to up to 50 million euros in Indian rupees. The joint venture will enable the production of finished products for the new markets, including the Indian market.

23. 1. 2024

Excellence is not an act, but a habit

In this year’s Slovenian Business Excellence survey, conducted by an independent external agency for the fifth year in a row, Krka once again scored highly across key parameters, winning the top place among 54 surveyed companies according to both the business community and the general public, and thus maintaining its leading position among Slovenian companies.

Share information

KRKGClose price118.00Change+0.43 %

2024-02-09 16:02

Data delayed 15 minutes.
Data source: LJSE.

29/1
202430/1
202431/1
20241/2
20242/2
20245/2
20246/2
20247/2
20249/2
2024

STABLE DIVIDEND GROWTH STRATEGY

We pursue a long-term strategy of stable dividend growth and allocate at least 50% of net profit of majority shareholders for dividends each year. From 2012 to 2022, the gross dividend per share increased on average by 14.1%.

29.1. 2024,229705,116
30.1. 2024,314680,115
31.1. 2024,384080,116
1.2. 2024,466506,115
2.2. 2024,300897,115
5.2. 2024,328342,115.5
6.2. 2024,919352,117.5
7.2. 2024,1587517,117.5
9.2. 2024,425393,118

BECOME PART OF A DEDICATED TEAM

Employees are given optimum conditions for development. We quickly recognise their potential, encourage their creativity and value their dedication to work.

Movie about Krka

3:00

Our core business is development, production, marketing and sales of prescription pharmaceuticals, non-prescription products and animal health products.

Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.

Krka around the world